<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">06467</article-id><article-id pub-id-type="doi">10.7554/eLife.06467</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology</subject></subj-group></article-categories><title-group><article-title>The HIV-1 envelope protein gp120 is captured and displayed for B cell recognition by SIGN-R1<sup>+</sup> lymph node macrophages</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-19294"><name><surname>Park</surname><given-names>Chung</given-names></name><aff><institution content-type="dept">B-cell Molecular Immunology Section, Laboratory of Immunoregulation</institution>, <institution>National Institutes of Allergy and Infectious Diseases</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-27281"><name><surname>Arthos</surname><given-names>James</given-names></name><aff><institution content-type="dept">Immunopathogenesis Section, Laboratory of Immunoregulation</institution>, <institution>National Institutes of Allergy and Infectious Diseases</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-27282"><name><surname>Cicala</surname><given-names>Claudia</given-names></name><aff><institution content-type="dept">Immunopathogenesis Section, Laboratory of Immunoregulation</institution>, <institution>National Institutes of Allergy and Infectious Diseases</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-16586"><name><surname>Kehrl</surname><given-names>John H</given-names></name><aff><institution content-type="dept">B-cell Molecular Immunology Section, Laboratory of Immunoregulation</institution>, <institution>National Institutes of Allergy and Infectious Diseases</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country><email>jkehrl@niaid.nih.gov</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1153"><name><surname>Nussenzweig</surname><given-names>Michel</given-names></name><role>Reviewing editor</role><aff><institution>Rockefeller University</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>10</day><month>08</month><year>2015</year></pub-date><volume>4</volume><elocation-id>e06467</elocation-id><supplementary-material><ext-link xlink:href="elife-06467-supp-v2.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>13</day><month>01</month><year>2015</year></date><date date-type="accepted"><day>08</day><month>08</month><year>2015</year></date></history><permissions><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><abstract><p>The HIV-1 envelope protein gp120 is both the target of neutralizing antibodies and a major focus of vaccine efforts; however how it is delivered to B cells to elicit an antibody response is unknown. Here, we show that following local gp120 injection lymph node (LN) SIGN-R1<sup>+</sup> sinus macrophages located in interfollicular pockets and underlying SIGN-R1<sup>+</sup> macrophages form a cellular network that rapidly captures gp120 from the afferent lymph. In contrast, two other antigens, phycoerythrin and hen egg lysozyme, were not captured by these cells. Intravital imaging of mouse LNs revealed persistent, but transient interactions between gp120 bearing interfollicular network cells and both trafficking and LN follicle resident gp120 specific B cells. The gp120 specific, but not the control B cells repetitively extracted gp120 from the network cells. Our findings reveal a specialized LN antigen delivery system poised to deliver gp120 and likely other pathogen derived glycoproteins to B cells.</p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author keywords</title><kwd>B lymphocyte</kwd><kwd>gp120</kwd><kwd>HIV-1</kwd><kwd>lymph node</kwd><kwd>vaccine</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (LIR-15) of the National Institute of Allergy and Infectious Diseases.</p></fn></fn-group></back></article>